
Sarepta Therapeutics (SRPT) Stock Forecast & Price Target
Sarepta Therapeutics (SRPT) Analyst Ratings
Bulls say
Sarepta Therapeutics is supported by a strengthening Elevidys franchise, with interim Phase IV ENDURE data showing no acute liver injury in 11 patients receiving prophylactic sirolimus and no treatment-related ALI or immunosuppression-related TEAEs across ambulatory and non-ambulatory groups. The exploratory PRO analysis also suggests meaningful mobility preservation versus external controls, while the REGENX/UPenn patent dispute settlement for $39M removes a legal overhang around AAV manufacturing technology. Combined with the gain from sale of a Priority Review Voucher, these developments improve product durability, de-risk execution, and reinforce a favorable fundamental outlook.
Bears say
Sarepta Therapeutics is facing a weakened investment case because ELEVIDYS still lacks convincing randomized proof on the core NSAA endpoint, while the company increasingly relies on external controls that do not match EMBARK’s placebo arm and may be distorted by missing data and assumptions. Commercially, the U.S. ELEVIDYS franchise remains under pressure, with 2Q26 revenue of $98.1M declining 3.8% quarter over quarter, and management’s 2026 rebuild thesis depends on evidence that has not yet shown functional benefit in toddlers or fully resolved efficacy doubts. Added to that are meaningful safety and adoption risks, including 7% to 9% serious ALI rates, payer resistance, and potential PMO erosion, which together limit upside and support a negative outlook.
This aggregate rating is based on analysts' research of Sarepta Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Sarepta Therapeutics (SRPT) Analyst Forecast & Price Prediction
Start investing in Sarepta Therapeutics (SRPT)
Order type
Buy in
Order amount
Est. shares
0 shares